|
시장보고서
상품코드
2024696
스마트 흡입기 시장 보고서 : 제품별, 적응증별, 유통 채널별, 지역별(2026-2034년)Smart Inhalers Market Report by Product, Indication (Asthma, Chronic Obstructive Pulmonary Disease ), Distribution Channel, and Region 2026-2034 |
||||||
세계의 스마트 흡입기 시장 규모는 2025년에 3억 6,210만 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 16억 4,190만 달러에 달하며, 2026-2034년에 CAGR 17.74%로 성장할 것으로 예측하고 있습니다.
스마트 흡입기는 복약 순응도를 모니터링하고, 투약 알림을 전송하며, 블루투스를 통해 쉽게 공유할 수 있는 정보에 대한 액세스를 제공하고, 투약 횟수와 시간, 장소를 정확하게 기록할 수 있는 호흡기용 흡입기입니다. 또한 치료 순응도 향상, 증상 관리에 대한 환자의 참여와 동기 부여를 돕고, 환자의 흉부에 영향을 미칠 수 있는 환경 및 기상 조건에 대한 보고서를 제공할 수 있습니다. 천식 및 만성폐쇄성폐질환(COPD)의 유병률이 증가함에 따라 전 세계에서 스마트 흡입기에 대한 수요가 증가하고 있습니다.
스마트 흡입기 시장 동향:
전 세계에서 대기오염이 악화되면서 만성 호흡기 질환(CRD), 폐암, 만성 기관지염, 급성 하기도 감염(ALRI) 환자 수가 크게 증가하고 있습니다. 이는 시장 성장을 촉진하는 주요 요인 중 하나가 되고 있습니다. 또한 기존 흡입기는 잘못된 흡입 방법이나 낮은 복약 순응도로 인해 효과가 떨어질 수 있으며, 이로 인해 환자의 병세가 악화될 수 있습니다. 그러나 스마트 흡입기는 투약 일정 및 용량 모니터링을 위해 모바일 앱과 연동되도록 설계된 디지털 기능을 활용하여 이러한 질병 관리에 있으며, 환자와 의료진의 어려움을 해결할 수 있습니다. 또한 증상에 따라 특정 대응이 필요한 경우 환자와 임상의에게 알림을 보내 보다 적절한 자가 관리로의 전환을 촉진할 수 있습니다. 이와 더불어 최근 스마트 흡입기 기술의 발전으로 사용자에게 흡입 방법의 피드백 및 적절한 복약 순응도 계산을 제공할 수 있는 스마트 흡입기 기술이 시장을 주도하고 있습니다. 또한 환자들 사이에서 스마트 흡입기 사용의 이점에 대한 인식이 높아진 것도 전체 매출과 수익성 향상에 기여할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 스마트 흡입기 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 적응증별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porters Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.05.18The global smart inhalers market size reached USD 362.1 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,641.9 Million by 2034, exhibiting a growth rate (CAGR) of 17.74% during 2026-2034.
Smart inhalers are respiratory inhalers that can monitor adherence, send dosage reminders, offer access to readily shareable information via Bluetooth, and record the time, date and location of each dosage administered accurately. They can also help improve compliance with therapy, increase patient involvement and motivation in controlling symptoms, and provide reports about environmental and weather conditions that may affect their chest. Due to the growing prevalence of asthma and chronic obstructive pulmonary diseases (COPD), there is a rise in the demand for smart inhalers across the globe.
SMART INHALERS MARKET TRENDS:
Due to a rise in air pollution levels worldwide, there is a significant increase in the number of patients with chronic respiratory diseases (CRDs), lung cancer, chronic bronchitis, and acute lower respiratory infections (ALRI). This represents one of the key factors propelling the growth of the market. Moreover, the efficacy of conventional inhalers can be negatively impacted by incorrect inhaler techniques and poor adherence, which may result in the progression of patients' condition. However, smart inhalers can address the challenges of patients and healthcare professionals in the management of these diseases using digital features designed to connect with mobile applications for monitoring medication schedules and subsequent dosing. Additionally, they can alert patients and clinicians when symptoms require specific action and facilitate a shift to better self-care. This, coupled with recent advances in smart inhaler technology, which allow feedback to users on their inhaler technique and the calculation of the correct level of adherence, is driving the market. Besides this, the increasing awareness about the benefits of using smart inhalers among patients is projected to augment the overall sales and profitability.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Inhalers
- Dry Powdered Inhaler
- Metered Dose Inhaler
- Nebulizers
Breakup by Indication:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Adherium Limited, AptarGroup Inc., AstraZeneca plc, Boehringer Ingelheim, Cognita Labs, GlaxoSmithKline plc, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG, Teva Pharmaceutical Industries Ltd. and Vectura Group Limited (Philip Morris International Inc.).
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Smart Inhalers Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Inhalers
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Dry Powdered Inhaler
- 6.1.2.2 Metered Dose Inhaler
- 6.1.3 Market Forecast
- 6.2 Nebulizers
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Indication
- 7.1 Asthma
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Chronic Obstructive Pulmonary Disease (COPD)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 3M Company
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Adherium Limited
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 AptarGroup Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 AstraZeneca plc
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Boehringer Ingelheim
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Cognita Labs
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 GlaxoSmithKline plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Novartis AG
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 OPKO Health Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Propeller Health (ResMed)
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 Sensirion AG
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.12 Teva Pharmaceutical Industries Ltd.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.13 Vectura Group Limited (Philip Morris International Inc.)
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials
- 14.3.13.4 SWOT Analysis
- 14.3.1 3M Company
